Project Grant R01HL167383
Award Date
5/15/24
Completion Date
4/30/28
Dollars Obligated
$1.3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,753.90 to Bloodworks (doing business as Puget Sound Blood Center and Program) from August 1, 2024 to July 31, 2027. The grant supports research to examine the role of thiol isomerases, particularly protein disulfide isomerase (PDI), in promoting redox-sensitive vaso-occlusion in sickle cell disease. The research aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $151,523 to investigate the role of fibrinogen in regulating thromboinflammation in acute and chronic venous thrombosis. The 5-year project aims to use novel RNA therapy with small interfering RNA (siRNA) delivered via lipid nanoparticles to selectively reduce circulating fibrinogen levels. Researchers at The Medical College of Wisconsin,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports a $2,070,048 research program focused on understanding the cellular and molecular mechanisms of atherosclerosis, a leading cause of cardiovascular disease (CVD). The overarching goal is to examine how inflammation and macrophage efferocytosis (clearance of dead cells) regulate plaque stability, with the aim of developing novel CVD treatments....
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $190,491 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research on plasma protein markers associated with blood pressure response during exercise. The key objectives are to: Identify circulating proteins related to exercise blood pressure that may be predictive of future hypertension and cardiovascular disease risk, using...
This federal Project Grant award of $552,413 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research conducted by Thomas Jefferson University (Sidney Kimmel Medical College) to investigate the use of short interfering RNAs (siRNAs) to modulate platelet and megakaryocyte gene expression and function. The key objectives of this 4-year project (April 2025 to January 2029) are: 1) Evaluate in vivo knockdown of...
This $674,338 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to elucidate the genetic architecture regulating tissue factor (TF) expression across human tissues and disease states. The research aims to identify rare human genetic variation in the TF-encoding F3 gene promoter, coding region, and 3' untranslated region that may disrupt TF regulation and contribute to...
This federal Project Grant award of $503,637, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to investigate the mechanisms of thrombosis (blood clot formation) associated with SARS-CoV-2 infection and COVID-19. The project will longitudinally follow patients from initial COVID-19 diagnosis through 6 months post-infection to identify changes in the hemostatic (blood clotting) and fibrinolytic (clot...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $5,154,906 in funding to Versiti Wisconsin, Inc. to conduct a coordinated, multi-disciplinary investigation of molecular mechanisms underlying immune-mediated thrombocytopenic and thrombotic disorders. The overarching goals are to build a deeper understanding of clinically relevant immunological insults that lead to thrombocytopenia...
This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...
This Project Grant award of $438,682 by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the natural history of silent cerebral infarction (SCI) and establish the incidence and risk factors for new SCI and stroke during remission in patients with immune thrombotic thrombocytopenic purpura (iTTP). The award will also evaluate the impact of the anti-VWF therapy caplacizumab on the prevalence of SCI and cognitive impairment in iTTP...